dihydergot 2.5mg tablets
novartis pharmaceuticals australia pty ltd - dihydroergotamine mesylate - tablets - 2.5mg - antimigraine preparations
sporanox oral solution
j-c health care ltd - itraconazole - solution - itraconazole 10 mg/ml - itraconazole - itraconazole - sporanox oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. prevention of fungal infection during neutropenia of immunodeficient patients.
cafergot tabs.
ergotamine tartrate 1mg caffeine 100mg
norvir tablets 100 mg
abbvie pte. ltd. - ritonavir - tablet, film coated - 100.0 mg - ritonavir 100.0 mg
klacid 250mg film-coated tablets
abbott laboratories limited - clarithromycin 250 mg - film-coated tablet
klacid 500mg film-coated tablets
abbott laboratories limited - clarithromycin 500 mg - film-coated tablet
klacid xl 500mg modified-release tablets
abbott laboratories limited - clarithromycin 500 mg - modified-release tablet
vicks sinex decongestant nasal spray
procter & gamble (health & beauty care) limited the heights brooklands, weybridge, surrey kt13 0xp, united kingdom - oxymetazoline - nasal spray, solution - oxymetazoline 0.05 % (w/v) - nasal preparations
vfend
pfizer europe ma eeig - voriconazole - candidiasis; mycoses; aspergillosis - antimycotics for systemic use - voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.
evotaz atazanavir/cobicistat 300 mg/150 mg film coated tablets bottle
bristol-myers squibb australia pty ltd - cobicistat, quantity: 150 mg; atazanavir, quantity: 300 mg - tablet, film coated - excipient ingredients: stearic acid; croscarmellose sodium; hyprolose; crospovidone; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide red - evotaz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults.